Pays: États-Unis
Langue: anglais
Source: NLM (National Library of Medicine)
CARISOPRODOL (UNII: 21925K482H) (CARISOPRODOL - UNII:21925K482H)
RedPharm Drug, Inc.
CARISOPRODOL
CARISOPRODOL 350 mg
ORAL
PRESCRIPTION DRUG
CARISOPRODOL is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. CARISOPRODOL should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [SEE DOSAGE AND ADMINISTRATION (2)]. CARISOPRODOL is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. 8.1 Pregnancy: Category Pregnancy C. There are no data on the use of CARISOPRODOL during human pregnancy. Animal studies indicate that CARISOPRODOL crosses the placenta and results in adverse effects on fetal growth and postnatal survival. The primary metabolite of CARISOPRODOL, meprobamate, is an approved anxiolytic. Retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased r
350 mg Tablets: White to off white, Round convex tablets, debossed with ‘CL’ above ‘022’ on one side available in: Bottles of 100 NDC 64980-174-01. Bottles of 500 NDC 64980-174-05. Bottles of 1000 NDC 64980-174-10. Storage: Store at controlled room temperature 20° - 25°C (68° - 77°F). [See USP Controlled Room Temperature]
Abbreviated New Drug Application
CARISOPRODOL- CARISOPRODOL TABLET REDPHARM DRUG, INC. ---------- CARIS OPRODOL HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CARISOPRODOL safely and effectively. See full prescribing information for CARISOPRODOL CARISOPRODOL Tablets for Oral Use CIV Initial U.S. Approval: 1959 RECENT MAJOR CHANGES Warnings and Precautions, Sedation(5.1) 10/2009 Warnings and Precautions, Drug Dependence, Withdrawal, and Abuse (5.2) 10/2009 INDICATIONS AND USAGE CARISOPRODOL is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions. (1) Important Limitations: Should only be used for acute treatment periods up to two or three weeks(1) Not recommended in pediatric patients less than 16 years of age(8.4) DOSAGE AND ADMINISTRATION Recommended dose is 350 mg three times a day and at bedtime.(2) DOSAGE FORMS AND STRENGTHS Tablets: 350 mg (3) CONTRAINDICATIONS Acute intermittent porphyria (4) Hypersensitivity reactions to a carbamate such as meprobamate (4) WARNINGS AND PRECAUTIONS Due to sedative properties, may impair ability to perform hazardous tasks such as driving or operating machinery (5.1) Additive sedative effects when used with other CNS depressants including alcohol (5.1) Cases of Drug Dependence, Withdrawal, and Abuse (5.2) Seizures (5.3) ADVERSE REACTIONS Most common adverse reactions (incidence > 2%) are drowsiness, dizziness, and headache (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Ingenus Pharmaceuticals NJ at 1-877-748- 1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) – additive sedative effects ( 5.1 and 7.1) See 17 for PATIENT COUNSELING INFORMATION. Revised: 12/2017 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORM AND STRENGTH 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Sedation 5.2 Drug Dependence, Withdrawal, and Abuse 5.3 Seizures 6 ADV Lire le document complet